NR3C2 and type 2 diabetes mellitus: Accordingly, the use of mineralocorticoid receptor (MR) antagonists increases the life expectancy of patients with severe heart failure, ameliorates nephropathy in type 2 diabetes, and reverses hypertension- and diabetes-associated vascular dysfunction [13,14,15,18].